Neoantigen Vaccines for Personalized Immunotherapy

C.E. Credits: P.A.C.E. CE Florida CE
Speaker
  • Associate Professor of Biomedical Informatics, Division of Computational Biology, Department of Quantitative Health Sciences, Mayo Clinic
    BIOGRAPHY

Abstract

Summary: Cancer neoantigens are highly specific to the tumor, potently immunogenic and can be targeted by both vaccines and engineered cellular therapies. This talk will introduce the definition of cancer neoantigens, review the neoantigen source, and discuss the challenges of neoantigen discovery from tumor genomic sequencing data.  In addition, I will talk about a phase-I clinical trial design for neoantigen vaccine therapy at Mayo Clinic.

Background: Immune Checkpoint Inhibitors (ICI) and Chimeric Antigen Receptor T-cells (CAR-T) are the two major immunotherapies that have revolutionized cancer treatments. Despite the immense promise of immunotherapies in treating various cancers, there have been a wide range of responses from patients. The percent of US patients with cancer who are eligible for ICI drugs increased to 43.63% in 2018 however only 12.46% of these patients are estimated to respond to ICI treatments. CAR-T has reached revolutionary milestone in treatment of hematological malignancies. However, CAR-T has not been yet successful in treating solid cancers due to the limited repertoire of cell-surface antigens and its ineffectiveness of infiltrating into solid tumor tissues. Furthermore, CAR-T therapy is not tumor-specific. The surface proteins targeted by CAR-T to-date are also expressed on normal cells resulting in on-target off-tumor and even off-target toxicities. In addition, significant challenges have been mounting to overcome treatment resistance and to improve efficacy. Strategies such as the combination immunotherapies of existing agents have so far yielded more failures than successes in this effort. Therefore, we have reached a critical point where it’s essential to search for and develop the novel next generation immunotherapy agents. Cancer neoantigens are among the most promising novel agents. 
 
 
Learning Objectives: 

1.    Discuss the different types of tumor somatic mutations that are sources of neoantigens.

2.    Break down the bioinformatics approaches for neoantigen identification from genomic sequencing data.

3.    Discuss basic design for phase-I neoantigen clinical trials.


Show Resources
You May Also Like
SEP 14, 2021 7:00 AM PDT
C.E. CREDITS
SEP 14, 2021 7:00 AM PDT
Date: September 14, 2021 Time: 7am PDT, 10am EDT, 4pm CEST A conventional thermal cycler has long been a commodity product in the lab and end-point PCR techniques can be completed almost wit...
SEP 17, 2021 12:00 PM CST
C.E. CREDITS
SEP 17, 2021 12:00 PM CST
Date: September 16, 2021 Time: 9:00pm (PDT), 12:00am (EDT) 3D cellular models like organoids and spheroids offer an opportunity to better understand complex biology in a physiologically rele...
NOV 09, 2021 11:00 AM PST
C.E. CREDITS
NOV 09, 2021 11:00 AM PST
Date: November 09, 2021 Time: 11:00am (PDT), 02:00pm (EDT) Clinical translation of human pluripotent stem cells (hPSCs) requires advanced strategies that ensure safe and robust long-term gro...
DEC 01, 2021 7:00 AM PST
C.E. CREDITS
DEC 01, 2021 7:00 AM PST
Date: December 01, 2021 Time: 7:00am (PST), 10:00am (EST) In the era of immuno-oncology, there is a growing need for the identification of new biomarkers predictive for sensitivity to anti-P...
OCT 27, 2021 6:00 AM PDT
C.E. CREDITS
OCT 27, 2021 6:00 AM PDT
Date: October 27, 2021 Time: 6:00 AM PDT, 9:00 AM EDT Etanercept is a recombinant Fc fusion protein therapeutic that has a complex distribution of post-translation modifications (PTM), such...
OCT 13, 2021 7:00 AM PDT
C.E. CREDITS
OCT 13, 2021 7:00 AM PDT
Date: October 13, 2021 Time: 7:00am (PDT), 10:00am (EDT) Western blot analysis is a method widely used in the lab today because of its versatility in detecting and measuring specific target...
Loading Comments...
Show Resources